ASH 2022 Conference Review focus on Lymphoma

In this edition:

Long-term outcomes of de-escalation of chemo in advanced Hodgkin Lymphoma
eBEACOPP vs. BrECADD & TRMB in advanced stage classical -  Hodgkin Lymphoma
NICE chemo as first salvage treatment in RR-HL
TRIANGLE: Ibrutinib + standard first-line treatment in younger mantle cell lymphoma patients
R-DeVIC vs. HDC-ASCT as consolidation therapy in PCNSL
PolaR-ICE as second-line therapy in RR-LBCL
Glofitamab-induced CR beyond end-of-treatment in RR-LBCL
Epcoritamab with rituximab + lenalidomide for follicular lymphoma
Mosunetuzumab in RR-FL for patients with ≥2 prior therapies
FLIPI24: An improved risk-prediction model for early events in follicular lymphoma
 

Please login below to download this issue (PDF)

Subscribe